Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2023 Medicom Conference Planning
  • Conference Proceedings
  • Disease Areas
  • Other Medical News
  • Media
    • Podcast
    • Video
    • Education
  • About
    • Conference Proceedings
    • Vacancies

Tag: Renal Cell Carcinoma

Triple therapy improves progression-free survival in patients with advanced RCC versus dual therapy

Presented By
Prof Toni Choueiri, Dana-Farber Cancer Institute, MA, USA
Trial
Phase 3, COSMIC-313
Conference
ESMO 2022

17 November, 2022 00:41

Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence

Presented By
Dr Axel Bex, The Royal Free London NHS Foundation Trust, UK
Trial
Phase 3, IMmotion-010
Conference
ESMO 2022

17 November, 2022 00:28

Exploratory treatment options fail in ccRCC 

Presented By
Prof. Thomas Powles, University of London, UK
Trial
Phase 2, CALYPSO
Conference
ASCO 2022

5 August, 2022 14:18

Adjuvant everolimus did not benefit high-risk renal cell carcinoma 

Presented By
Dr Christopher W. Ryan, Oregon Health & Science University, OR, USA
Trial
Phase 3, EVEREST
Conference
ASCO 2022

5 August, 2022 14:14

High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib

Presented By
Dr Axel Bex, Netherlands Cancer Institute, the Netherlands
Trial
Phase 2, NeoAvAx
Conference
ASCO GU 2022

8 April, 2022 11:14

DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up

Presented By
Dr Toni Choueiri, Dana-Farber Cancer Institute, MA, USA
Trial
Phase 3, KEYNOTE-564
Conference
ASCO GU 2022

8 April, 2022 11:14

Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC

Presented By
Dr Marc-Oliver Grimm, University Hospital Jena, Germany
Trial
Phase 2, TITAN-RCC
Conference
ASCO GU 2022

8 April, 2022 11:13

Combined nivolumab/axitinib treatment elicits good response in metastatic RCC

Presented By
Dr Matthew Zibelman, Fox Chase Cancer Center, PA, USA
Trial
Phase 1/2
Conference
ASCO GU 2022

8 April, 2022 11:13

Folliculin mutations not associated with sporadic chromophobe RCC

Presented By
Dr Joseph Jacob, Upstate University Hospital, NY, USA
Conference
ASCO GU 2022

8 April, 2022 11:13

Differential patterns of molecular alterations among sites of metastasis in RCC

Presented By
Dr Rana McKay, University of California San Diego, CA, USA
Conference
ASCO GU 2022

8 April, 2022 11:12

Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC

Presented By
Dr Michael Atkins, Georgetown Lombardi Comprehensive Cancer Center, DC, USA
Trial
Phase 2, HCRN GU16-260
Conference
ASCO GU 2022

8 April, 2022 11:12

ASCO GU 2022 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ASCO GU 2022

14 March, 2022 07:21

TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC

Presented By
Prof. Janet Brown, University of Sheffield, UK
Trial
Phase 2, STAR
Conference
ESMO 2021

19 November, 2021 09:26

Modified ipilimumab schedule reduces risk of grade 3/4 adverse events

Presented By
Dr Naveen Vasudev, St James University Hospital, UK
Trial
Phase 2, PRISM
Conference
ESMO 2021

19 November, 2021 09:26

EAU TV: The best on bladder cancer and renal cell carcinoma

Presented By
Prof. Arnulf Stenzl
Conference
EAU 2021

31 August, 2021 12:29

Best of EAU: Immune cell populations have prognostic value in RCC

Presented By
Dr Alberto Breda, Autonomous University of Barcelona, Spain
Conference
EAU 2021

31 August, 2021 12:28

KEYNOTE-564: First positive phase 3 results with adjuvant checkpoint inhibition in RCC

Presented By
Prof. Thomas Powles, Barts Cancer Centre, London, UK
Trial
Phase 3, KEYNOTE-564
Conference
EAU 2021

31 August, 2021 12:28

PSMA PET-CT more accurate than standard-of-care imaging in RCC

Presented By
Dr Arsalan Tariq , Royal Brisbane and Women's Hospital, Australia
Conference
EAU 2021

31 August, 2021 12:28

CheckMate 9ER offers RCC new frontline option; perspectives from the study’s principle investigator

Principal Investigator
Prof. Toni Choueiri, Dana Farber Cancer Institute, Harvard University, Boston, USA
Trial
Phase 3, CheckMate 9ER
Conference
ESMO Virtual Congress 2020

15 December, 2020 15:49

KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib

Presented By
Prof. Jens Bedke, University of Tübingen, Germany
Trial
Phase 3, KEYNOTE-426
Conference
EAU 2020

20 August, 2020 10:41

Debate: upfront cytoreductive nephrectomy or not?

Presented By
Prof. Axel Bex & Prof. Antonio Finelli
Trial
Phase 3, CARMENA; SURTIME
Conference
EAU 2020

20 August, 2020 09:29
site created by:   

© 2023 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy